Navigation Links
In the quest for safer treatment for systemic lupus erythematosus

This news release is available in Spanish.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. It can affect various organs, in particular, the skin, joints and kidneys although it displays great variability in extent and seriousness depending on the patient. Approximately nine out of every ten patients are female and it appears in one woman in every thousand.

As Dr Guillermo Ruiz-Irastorza, head of the Autoimmune Disease Research Unit of the Hospital Universitario Cruces, explained, traditionally lupus has been treated mostly with glucocorticoids (prednisone), despite the fact that its severe side effects have been known for years. "We doctors knew that administering high doses of prednisone in an ongoing way caused irreversible damage like osteoporosis, avascular necrosis of bone, diabetes or cataracts. However, the tendency was to accept these side effects as an inevitable price to pay in exchange for controlling the disease".

Yet recent studies by this same group indicate that lower doses of glucocorticoids could be just as effective. What is more, in more serious forms, pulsed therapy, in other words, the intermittent intravenous administering of high doses is highly effective and probably does not lead to so many adverse effects.

So the researchers at the Hospital Universitario Cruces decided to study the relation between treatment with prednisone administered orally over 4 years from the moment of diagnosis and the damage built up over the first 5 years. To complete the study, they also looked at the effect of another glucocorticoid, methylprednisolone, administered intravenously at high doses and intermittently, at the moments when the disease manifests itself with increased severity.

230 patients, 206 of whom were women, took part in the study. The average age when they were diagnosed with lupus was 35.75 years.

"We saw that by the end of the fourth year most of them, 80%, had been treated with prednisone at some point, and by the fifth year nearly 4 out of every 10, 37.8%, had developed damage," pointed out Dr Ruiz-Iraztorza. Significantly, the patients with damage had received higher doses of prednisone (10.4 mg/day as opposed to 6 mg/day in the patients without damage). In the specific study of the damage that could be directly attributed to the use of glucocorticoids, the results were similar, with average daily doses of 11 vs. 7 mg/day, respectively. And it does not stop there. As previous studies had suggested, they proved that the association with damage began with average doses of 7.5 mg/day. "In other words, above that dose, permanent side effects may appear." By contrast, pulsed methylprednisolone therapy was not associated with any kind of damage.

Anti-malarial drugs for treating lupus

The research carried out by the group at the Hospital Universitario Cruces has been published in the specialised journal Rheumatology. In fact, these results have confirmed that the guidelines used in the Auto-immune Disease unit of the Hospital Universitario Cruces for several years are good. Dr Ruiz-Irastorza stresses that the background treatment in patients with SLE has to be anti-malarial drugs, specifically hydroxychloroquine, since, as he maintains, "it has been proven that they are more effective in the long term than glucocorticoids for controlling lupus and, at the same time, they have far fewer side effects. The role of the latter needs to be restricted to managing periods during which the disease flares up."

"The beneficial effect of anti-malarial drugs on SLE was discovered by accident during the Second World War," explained the doctor. "In any case, as prolonged background treatment they were seen to be ideal for controlling lupus, even as a monotherapy in many patients with proven effects on long-time survival. So we reserve glucocorticoids to be administered when the disease flares up, and we know that in more serious cases we can administer pulsed methylprednisolone safely and effectively. For maintenance treatment, the prednisone dose must not exceed 5 mg/day so on occasions we have to add other immunosuppressive drugs. We believe that these combined guidelines that we use constitute a safer and more effective alternative for patients with SLE."


Contact: Matxalen Sotillo
University of the Basque Country

Related medicine news :

1. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
2. When to have kids: A complex question for hazel dormice
3. Weirdest hCG Questions Revealed
4. New Polar RCX3 Heart Rate Monitor Versus Suunto Quest
5. Progress in quest to reduce use of radiation in treatment of pediatric Hodgkin lymphoma
6. Medtronic Infuse Bone Graft Questioned As Allegations Unfold – Bisnar
7. Chase Attorneys Offer Free Consultations
8. HCOs find risks & opportunities in quest for reduced costs & improved quality
9. Health care organizations quest for reduced costs and improved quality
10. Study questions value of calcium and vitamin D supplements
11. Study Questions Guidelines on Radiation for Older Breast Cancer Patients
Post Your Comments:
Related Image:
In the quest for safer treatment for systemic lupus erythematosus
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... the possibilities are endless. Users have full control over angle of view, speed method, ... users are sure to get heads to turn. , ProPanel: Pulse offers fully customizable ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... out by the University of Toronto and the University of British Columbia suggested that ... for head injuries. The article explains that part of the reason for the controversial ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that ... ). More than 3.7 billion people under the age of 50 – or 67% ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Linden Care, ... and optimizing treatment outcomes for patients suffering from chronic ... request for a Temporary Restraining Order (TRO) enjoining Express ... the two companies. --> ... pursuing all of its legal options. ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
Breaking Medicine Technology: